Foresight Biotherapeutics' FST-100 Reduces Infectious Adenoviral Titers and Improves Clinical Signs in Conjunctivitis Model

NEW YORK--(BUSINESS WIRE)--Foresight Biotherapeutics, Inc. today announced data from a pre-clinical study designed to assess the safety and efficacy of the topical administration of FST-100 in a widely accepted rabbit model of adenoviral conjunctivitis. Adenoviral titer data demonstrated that FST-100 was able to reduce titers to a greater degree than either saline or Tobradex® (p = 0.05) and was equally as effective as cidofovir. Cidofovir is the standard active control in this model but has shown ocular toxicity in human testing. FST-100 also demonstrated a clinically and statistically significant (p = 0.05) reduction in signs of adenoviral conjunctivitis versus all other groups tested including saline, Tobradex® and cidofovir. The study was conducted at the Louisiana State University (LSU) Health Sciences Center, LSU Eye Center in New Orleans, Louisiana by Professor James M. Hill and colleagues. Data is being presented at the 2010 annual meeting of the Association for Research in Vision and Ophthalmology being held in Ft. Lauderdale, Florida.